Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Halia Therapeutics Bahrain Iran Iraq Jordan Kuwait Lebanon Oman Palestine Qatar Saudi Arabia Syria United Arab Emirates Yemen Utah

View original content:https://www.prnewswire.co.uk/news-releases/halia-therapeutics-completes-first-in-human-phase-1-study-of-ht-4253-a-novel-lrrk2-inhibitor-targeting-neuroinflammation-302482112.html